Targeted oncology
Idasanutlin in Combination with Chemotherapy or Venetoclax in Pediatric and Young Adult Patients with Relapsed/Refractory Solid Tumors (iMATRIX Idasa): Results of a Phase I/II, Multicenter, Multi-arm Study.
Alba Rubio-San-Simón, Lynley V Marshall, Francois Doz, Jaume Mora, Kevin Bielamowicz, Nadege Corradini, Anne-Marie Langevin, Aru Narendran, Amy A Smith, C Michel Zwaan, Deborah Gho, Alison Cardenas, Stephen Fowler, Cecile Guizani, Vanessa Breton
Published: 202510.1007/s11523-025-01186-w
Abstract
BACKGROUND: MDM2 regulates the P53 pathway and is a promising therapeutic target, particularly in pediatric cancers with wild-type (WT) TP53. Idasanutlin is an investigational MDM2 inhibitor that is highly selective and orally bioavailable. The combi…
Preview only. Read the full abstract at the source